Tri-Service General Hospital

Running trials

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Transversus Abdominis Plane and Rectus Sheath Block for Robotic Colectomy

  NCT07624916· Phase 4· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· AbbVie· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

  NCT07416526· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status

  NCT07597850· Phase 2· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs

  NCT07589322· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  NCT07415044· Phase 2· Eli Lilly and Company· Source

• Recruiting

  MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

  NCT07431827· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Eli Lilly and Company· Source

• Not yet recruiting

  To Investigate the Change of Brain and Autonomic Function From Different Protocols of Repeated Transcranial Magnetic Stimulation Therapy for Patients With Post-traumatic Stress Disorder Comorbid Major Depressive Disorder

  NCT07327385· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

  NCT07353931· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Janssen Research & Development, LLC· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

  NCT07227454· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

  NCT06981637· Phase 2· National Health Research Institutes, Taiwan· Source

• Recruiting

  A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

  NCT06908304· Phase 3· Maia Biotechnology· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy

  NCT07241182· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

  NCT06899126· Phase 3· Daiichi Sankyo· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

  NCT07136467· AbbVie· Source

• Not yet recruiting

  Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

  NCT07151326· Phase 2· National Health Research Institutes, Taiwan· Source

• Not yet recruiting

  Taiwanese Anaplastic Thyroid Cancer Registry

  NCT07138261· National Health Research Institutes, Taiwan· Source

• Recruiting

  Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development

  NCT06847932· National Defense Medical Center, Taiwan· Source

• Recruiting

  Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  NCT06787612· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source

• Recruiting

  Effectiveness of Early Intervention With Virtual Reality-Based Interactive Rehabilitation on Upper Extremity Muscle Strength, Cognitive Status, Hospital Anxiety, and Exercise Self-Efficacy in Patients With Acute Ischemic Stroke

  NCT07674329· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

  NCT06772623· Phase 1/2· AbbVie· Source

• Recruiting

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

  NCT06543914· AbbVie· Source

• Not yet recruiting

  iTBS in MCI and Mild AD

  NCT06670820· National Defense Medical Center, Taiwan· Source

• Active, not recruiting

  A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

  NCT06311721· Phase 3· Amgen· Source

• Recruiting

  Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

  NCT06397911· Phase 2· Oneness Biotech Co., Ltd.· Source

• Active, not recruiting

  Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT06162572· Phase 1/2· Servier Bio-Innovation LLC· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

  NCT06475742· Phase 3· Viatris Innovation GmbH· Source

• Active, not recruiting

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia

  NCT07680959· Tri-Service General Hospital (TSGH)· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  NCT06330064· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  NCT06312137· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

  NCT06003387· Phase 3· CSL Behring· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

  NCT06097364· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  NCT05696626· Phase 3· LeonaBio· Source

• Active, not recruiting

  Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  NCT06008756· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

Showing 50 of 98.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer14 recruiting
• Colorectal cancer4 recruiting
• Liver and biliary tract cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Ovarian cancer3 recruiting
• Stroke3 recruiting
• Depression2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Follicular lymphoma2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Haemophilia2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• Obesity2 recruiting
• Pancreatic cancer2 recruiting
• Schizophrenia2 recruiting
• Alopecia areata1 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Cervical cancer1 recruiting
• Chronic kidney disease1 recruiting
• COPD1 recruiting
• Endometrial cancer1 recruiting
• Hidradenitis suppurativa1 recruiting
• Lupus (SLE)1 recruiting
• Melanoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoarthritis1 recruiting
• Osteoporosis1 recruiting
• Sarcoma1 recruiting
• Thyroid cancer1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

  NCT06921759· Phase 3· Eli Lilly and Company· Source

• Completed

  A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients

  NCT06745583· Phase 2· Elixiron Immunotherapeutics Inc.· Source

• Completed

  Efficacy of the Pelvic Clock® Device for Functional Recovery After Robotic-Assisted Radical Prostatectomy

  NCT07333807· Tri-Service General Hospital (TSGH)· Source

• Completed

  A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.

  NCT06321510· Pfizer· Source

• Completed

  Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients

  NCT06381986· Phase 2· Sunhawk Vision Biotech, Inc.· Source

• Completed

  Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)

  NCT06353087· Pfizer· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  LungVision AI-Augmented Fluoroscopic Navigation for Intraoperative Pulmonary Nodule Localization

  NCT07682012· Tri-Service General Hospital (TSGH)· Source

• Completed

  A Study to Learn About Zavegepant as the Acute Treatment of Migraine in Asian Adults

  NCT05989048· Phase 3· Pfizer· Source

• Completed

  Family-based Frailty Self Management Model and the Effects of the FRAIL-SM Program Among Patients With Heart Failure

  NCT05765721· National Yang Ming Chiao Tung University· Source

• Completed

  Tele-Rehabilitative Exercise Training Program in Nurses With Long COVID

  NCT06840873· Shang-Lin Chiang· Source

• Completed

  Effects of Intravascular Laser Irradiation of Blood for Mitochondral Dysfunction in Cerebral Ischemic Stroke

  NCT06932627· Tri-Service General Hospital (TSGH)· Source

• Completed

  The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19

  NCT05922865· Shang-Lin Chiang· Source

• Completed

  Vibration Training for Patients With Chronic Stroke

  NCT07554794· CHIA-HUEI LIN, PhD· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients

  NCT06372834· Tri-Service General Hospital (TSGH)· Source

• Completed

  A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan

  NCT05684341· Sanofi· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC

  NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Completed

  A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

  NCT05133531· Phase 3· Regeneron Pharmaceuticals· Source

• Completed

  the Investigation of Therapeutic Effect After ILIB for Ischemic Stroke Patient

  NCT05456750· Tri-Service General Hospital (TSGH)· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Terminated

  A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus

  NCT05123586· Phase 2· Eli Lilly and Company· Source

• Completed

  Tele-exercise Training Program for Long COVID

  NCT07553897· Tri-Service General Hospital (TSGH)· Source

• Completed

  A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)

  NCT04968912· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Real-world Clinical Benefit Evaluation in Breast Cancer Patients With Pharmaceutical Interventions for Cancer-related Fatigue

  NCT05428527· National Defense Medical Center, Taiwan· Source

• Completed

  Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

  NCT04921384· Phase 3· H. Lundbeck A/S· Source

• Completed

  A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

  NCT04686136· Phase 3· AbbVie· Source

• Completed

  NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With Nintedanib

  NCT04614441· Boehringer Ingelheim· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Completed

  o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

  NCT07333976· Phase 2· Tri-Service General Hospital (TSGH)· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

  NCT03846310· Phase 1· Arcus Biosciences, Inc.· Source

• Completed

  PG2 Concurrent With Chemoradiation for Locally Advanced Esophageal Cancer

  NCT03611712· Phase 2· PhytoHealth Corporation· Source

• Completed

  Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  NCT03510871· Phase 2· National Health Research Institutes, Taiwan· Source

• Completed

  M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT03631706· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

  NCT07271446· Phase 1· Precision Biotech Taiwan Corp.· Source

• Terminated

  Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5

  NCT03520712· Phase 1/2· BioMarin Pharmaceutical· Source

• Completed

  Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

  NCT03370913· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

  NCT03412773· Phase 3· BeiGene· Source

• Completed

  A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

  NCT03234972· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma

  NCT03234595· Phase 1/2· Everfront Biotech Co., Ltd.· Source

• Terminated

  A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT03215030· Phase 1/2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

  NCT03069352· Phase 3· AbbVie· Source

• Completed

  Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

  NCT03025308· Phase 3· Alfasigma S.p.A.· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source

• Completed

  A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

  NCT02615691· Phase 3· Baxalta now part of Shire· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

  NCT02576431· Phase 2· Bayer· Source

Showing 50 of 52.

Conditions

Diseases this institution publishes on or runs trials for.

• Sjögren's disease7 works · 2 trials
• Haemophilia7 works · 6 trials
• Primary biliary cholangitis3 works · 0 trials